Biogen Inc. Board of Directors

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Mr. Christopher A. Viehbacher

Mr. Christopher A. Viehbacher

President, CEO & Director

Ms. Robin C. Kramer

Ms. Robin C. Kramer

Senior VP & Chief Accounting Officer

Mr. Tim Power M.B.A., Ph.D.

Mr. Tim Power M.B.A., Ph.D.

Head of Investor Relations

Dr. Ginger Gregory Ph.D.

Dr. Ginger Gregory Ph.D.

Executive VP & Chief Human Resources Officer

Mr. Adam Keeney Ph.D.

Mr. Adam Keeney Ph.D.

Executive VP & Head of Corporate Development

Ms. Nicole Murphy

Ms. Nicole Murphy

Head of Pharmaceutical Operations & Technology

Ms. Susan H. Alexander Esq.

Ms. Susan H. Alexander Esq.

Executive VP & Chief Legal Officer

Ms. Natacha Gassenbach

Ms. Natacha Gassenbach

Chief Communication Officer & Head of Corporate Affairs

Mr. Rachid Izzar

Mr. Rachid Izzar

Head of Global Product Strategy & Commercialization

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.